Biotage, a leading supplier of tools and technology for medicinal and analytical chemistry, now offers two product lines, which perform very well in solvent systems such as MeOH, MTBE, and ethyl acetate.
With the current shortage of Acetonitrile and availability now worsening this is important news. Biotage's polymer-based cartridges and 96-well plates are designed for Solid phase extraction (SPE) of acidic, basic and neutral compounds, providing efficient removal of salts, proteins, and phospholipids with a Methanol/Water generic methodology. ISOLUTE SLE+ and EVOLUTE will be showcased exclusively at booth #3673 at PITTCON 2009, McCormick Place, Chicago from 8-13 March 2009.
EVOLUTE ABN can be applied to a wide range of compounds with a single method. The EVOLUTE CX is a mixed mode hydrophobic/ionexchanger, optimized to give increased selectivity of basic compounds. Both phases are suitable for a range of industries including pharmaceuticals, clinical, forensic, toxicological, food, environmental, food safety and chemical.
ISOLUTE SLE+ (supported-liquid-extraction) plates and columns are designed for aqueous samples and mimic traditional liquid-liquid extraction. The ISOLUTE SLE+ and ISOLUTE HM-N employ water-immiscible solvents such as MTBE, ethyl acetate and DCM to achieve isolation of the desired analytes.
Endogenous compounds that often interfere with mass spec detection are efficiently removed with this technique. The format is compatible with automated instruments for increased throughput and performance.
For further press information please contact: Eleanor CallanMonk, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA T: +44 1477 539539 F: +44 1477 539540 E: biotage[.]scottpr.com
Biotage is a global company active in life science research with strong technologies, a broad range of operations and a long-term view of the market. The company offers solutions, knowledge and experience in the areas of genetic analysis and medicinal chemistry. In 2005 operations and products were acquired from the American company Argonaut, further strengthening the medicinal chemistry product range. The customers include the worlds top 30 pharmaceutical companies, the worlds top 20 biotech companies, and leading academic institutes. The company is headquartered in Uppsala and has offices in the U.S., Japan, UK, Germany and several other European countries.
Biotage has 336 employees and had sales of 496,4 MSEK in 2007. Biotage is listed on the OMX Nordic Exchange Stockholm AB.
Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "believe,"
"expect," "intend," and "should," among others. These forward-looking statements are based on Biotage's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Biotage notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations), variability of operating results, the commercial development of the microwave synthesis and flash purification in the drug discovery market, DNA sequencing and genomics market, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for Biotage's products (including seasonal fluctuations), difficulties in successfully adapting the Company's products to integrated solutions and producing such products, and the Company's ability to identify and develop new products and to differentiate its products from competitors.